Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Comment by dt_coreon Mar 22, 2011 9:45pm

276 Views

Post# 18325397

RE: RE: RE: Huge disappointment

Guidance is for $70mm, but after being questioned on the call Steven all but admitted this number was sand bagged. Accordingly, I think $75mm is the "real" guidance, with some upside (but don't expect HEM to mention this number publicly. They want to show they can beat their gudance and accordingly are being overly conservative.)

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!